MJardin Group Inc (OTCMKTS: MJARF) is a cannabis platform that has been operating in the legal market for a decade. Primarily, the company offers management services for a plethora of cannabis operators which include cultivation, processing, and retail.
The Colorado-based cannabis stock operates cultivation as well as retail operations in Canada and the U.S. Started by focusing on third-party managing facilities but has since concentrated towards the affiliated operations.
MJardin is a well-capitalized organization that continues to aim at a strategic expansion as well as M&A opportunities across the legal cannabis market.
MJardin Price Analysis
MJardin is trying from all angles to ensure that it gets things up and running once again from the recent swings. Notably, the pot stock is doing everything right to ensure it hits past its all-time high back sooner rather than later.
The stock has made a plethora of positive developments, but still, the price has edged lower with a bearish trend. For most, below the $2 level, it may seem like a concern, but things are no longer going to stay down (as it seems).
Currently, the stock is priced at $0.96 and showing some positive signs of getting on track. A bounce back is inevitable, given the positive developments signaling long-term growth.
What Makes MJardin Stock the Real Deal?
The company manages more than 36 cultivation, processing as well as retail facilities. Besides, in recent months, it has made several acquisitions that (in the long-term) will prove to be the game changers for the company.
For instance, the top of the list acquisition that sheds light on the stock’s long-term growth is that of Cannabella. It’s an operator of marijuana extraction facility and producer of edibles as well as topicals in Nevada.
Cannabella acquisition strengthens its extraction capabilities, especially in Nevada. Furthermore, it allows the company to enhance edibles as well as topical line and leverage a portion of the stock’s cultivation output.
Moreover, early this year, the company announced an agreement with Rama First Nation aiming to construct as well as operate a cultivation and retail complex. The joint venture is 49% owned by MJardin and 51% by Rama First Nation and receives over 3 million visitors annually.
Another significant stride made by the stock last month was paying-down the existing debt. The payment was obtained by an 11% sale of the company’s position in AtlantiCann Medical Inc. to the famous 13 Mi’kmaq Nova Scotia First Nations. Besides, the agreement allows it to explore several potential retail partnerships with those of Mi’kmaq.
Also, the company anticipates completing the construction of its 75% owned “GRO” facility. Once it’s completed, they’ll submit an Evidence of Readiness to Health Canada to receive a Cultivation and Processing License.
The developments have at least shown some positives with the company confirming its WILL facility based in Brampton Ontario having registered a high cannabis cultivation yields going past historical levels. It produced 62 grams of flowers on average as well as an additional extractable trim of 26 grams for a total of 87 grams per square foot.
Furthermore, the Q4 results showed an improvement as the revenue increased by 38% year-to-year to above $27.5 million. Consequently, everything is showing that the company is right on track and only a matter of time before it shoots up.
The share price might have dwindled, but the array of developments the company is taking will turn out to be the game changer. The company has made massive progress in strengthening its extraction capabilities.
Although the stock is trending lower, a breakthrough followed by a close over the $2 level should be happening anytime and reaffirm the company’s bounce back credentials.
For the latest updates on MJARF and the hottest MJ stocks, sign up below!
Disclosure: We have no position in MJARF and have not been compensated for this article.
Image courtesy of Pexels
What Do Investors See In Medical Marijuana Stock (OTCMKTS:MJNA)?
Medical Marijuana Stock (OTCMKTS:MJNA) has emerged as one of many investor’s favorite pot stocks in the legal cannabis universe in 2020. The stock is already up about 10% in 2020, demonstrating how investors have warmed up to the stock early on in the New Year.
Following a disastrous 2019, cannabis investors lost money but have also learned that their best bets are stocks with strong fundamentals. They are looking for companies that have positioned themselves well in the cannabis industry and have what it takes to go for the opportunities. That is why MJNA stock is catching a lot of investor attention in 2020 because of how it has positioned itself in the cannabis market.
Robust revenue growth and strong financial position have also helped put MJNA on the radar of investors hunting for quality cannabis stocks. Revenue at MJNA more than doubled from $26.5 million in 2017 to $60 million in 2018. MJNA is also not in financial distress as may be the case with other cannabis companies out there. The company finished the third quarter, the most recent reported period, with $5.5 million in cash reserves.
Moreover, MJNA has recently taken steps to expand into new international markets and invest in companies that are leaders in their segments. These prudent actions are helping lift Medical Marijuana stock as more investors learn about them.
About Medical Marijuana stock
Is Tilray Inc (NASDAQ:TLRY) A Buy Or Sell?
For Tilray Inc (NASDAQ:TLRY) and the rest of cannabis stocks, 2019 was no doubt a bad year. But 2020 is shaping up to be a promising year for the stock. To start with, Tilray stock has already gained 8.35% year-to-date. If that says anything, it shows following the broad selloff in Tilray stock last year, we’ve got to a point where sellers are giving way to buyers in the stock.
There are several catalysts that should continue driving NASDAQ:TLRY as you’re about to see. First, below is a brief profile of the company we’re discussing.
Tilray is a Canada-headquartered global cannabis company. It is engaged in activities of cannabis cultivation and processing as well as marketing and distribution of cannabis products. Tilray already has several cannabis products brands to its portfolio. It operates across five continents through subsidiaries in Canada, Australia, Germany, and Portugal.
Following the broad collapse of cannabis stocks in 2019, investors are looking for cannabis stocks that can make a positive impact on their portfolios in 2020. Tilray stands out as an attractive cannabis stock pick in 2020. Here are some of the exciting things about the company.
Tilray CEO sees a bright future for the cannabis industry
On January 25, Tilray CEO Brendan Kennedy spoke on Bloomberg. In that interview, Kennedy framed a rosy outlook for the…
Is Cronos Stock (TSE:CRON)(NASDAQ:CRON) A Buy?
Cronos Stock (TSE:CRON)(NASDAQ:CRON) stock fell 9.22% on January 24, marking its steepest decline so far in 2020. The stock plunge followed an important disclosure that you would only expect from a company that is trying to be straight and transparent with investors. Here’s what happened.
On January 22, after market close, Cronos made a regulatory filing detailing changes in its executive team. In that SEC filing, Cronos revealed that David Hsu and William Hilson have stepped down as its chief operating officer and chief commercial officer, respectively. Unfortunately, some investors read bad news in the executive exits and sold their shares in Cronos.
But a careful reading of the filing doesn’t seem to raise any red flags. Therefore, the big stock plunged points to investors panicking to the degree of responding to a mosquito bite with a missile.
There is no doubt that 2019 was a difficult year for cannabis stocks and Cronos Stock is no exception. But before the uncalled for reaction to Cronos’s regulatory filing, we had been at a point where sellers were starting to give way to buyers in Cronos stock. The stock has gained about 8.0% in the past one month. It had gained more than 13% year-to-date before the January 24 big selloff.
About Cronos Stock
Cronos Stock is a Canada-based global cannabis company. Cronos operates through subsidiaries and…